This “Wegener's Granulomatosis/Granulomatosis with Polyangiitis - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Wegener's Granulomatosis/Granulomatosis with Polyangiitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Wegener's Granulomatosis/Granulomatosis with Polyangiitis Understanding
Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis, is a rare multisystem autoimmune disease, characterized by inflammation of small- and medium-sized blood vessels (vasculitis) that results in damage to various organ systems of the body, most often the sinuses, trachea, lungs, and kidneys. The first sign of GPA may be a recurrent respiratory infection, or a cough or runny nose that continues for longer than expected. Other common symptoms of the disease include nosebleeds, joint pain, weakness, tiredness (fatigue), weight loss, or an unexplained fever. The diagnosis of GPA is made based upon a thorough clinical evaluation including routine laboratory tests, a detailed patient history, identification of relevant symptoms, and a variety of specialized tests. The treatment for GPA includes a combination of multiple medications. These medications typically include glucocorticoids such as prednisone and immunosuppressive drugs such as rituximab.
"Wegener's Granulomatosis/Granulomatosis with Polyangiitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wegener's Granulomatosis/Granulomatosis with Polyangiitis pipeline landscape is provided which includes the disease overview and Wegener's Granulomatosis/Granulomatosis with Polyangiitis treatment guidelines. The assessment part of the report embraces, in depth Wegener's Granulomatosis/Granulomatosis with Polyangiitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wegener's Granulomatosis/Granulomatosis with Polyangiitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Wegener's Granulomatosis/Granulomatosis with Polyangiitis R&D. The therapies under development are focused on novel approaches to treat/improve Wegener's Granulomatosis/Granulomatosis with Polyangiitis.
This segment of the Wegener's Granulomatosis/Granulomatosis with Polyangiitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Abatacept, sold under the brand name Orencia, inhibits T cell activation by selectively blocking specific binding of the CD80/CD86 receptor in APC to CD28 on T cells. The pharmacological strategy looks to inhibit the accelerated immune/inflammatory response, characteristic of the disease, and restore normal homeostasis in the immune system. The drug is currently in Phase III clinical studies for the treatment of relapsing, non-severe, granulomatosis with polyangiitis.
Vilobelimab (IFX 1; CaCP 29), is an anti-complement C5a monoclonal antibody. The drug is in Phase II clinical studies for the treatment of patients with granulomatosis with polyangiitis. Vilobelimab (IFX-1) holds large potential for treating various inflammatory disease and certain cancers and is in clinical testing for several indications, including hidradenitis suppurativa, ANCA-associated vasculitis and pyoderma gangraenosum.
This segment of the report provides insights about the different Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 2+ key companies which are developing the therapies for Wegener's Granulomatosis/Granulomatosis with Polyangiitis. The companies which have their Wegener's Granulomatosis/Granulomatosis with Polyangiitis drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Wegener's Granulomatosis/Granulomatosis with Polyangiitis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs.
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Wegener's Granulomatosis/Granulomatosis with Polyangiitis Understanding
Wegener's Granulomatosis/Granulomatosis with Polyangiitis: Overview
Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis, is a rare multisystem autoimmune disease, characterized by inflammation of small- and medium-sized blood vessels (vasculitis) that results in damage to various organ systems of the body, most often the sinuses, trachea, lungs, and kidneys. The first sign of GPA may be a recurrent respiratory infection, or a cough or runny nose that continues for longer than expected. Other common symptoms of the disease include nosebleeds, joint pain, weakness, tiredness (fatigue), weight loss, or an unexplained fever. The diagnosis of GPA is made based upon a thorough clinical evaluation including routine laboratory tests, a detailed patient history, identification of relevant symptoms, and a variety of specialized tests. The treatment for GPA includes a combination of multiple medications. These medications typically include glucocorticoids such as prednisone and immunosuppressive drugs such as rituximab.
"Wegener's Granulomatosis/Granulomatosis with Polyangiitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wegener's Granulomatosis/Granulomatosis with Polyangiitis pipeline landscape is provided which includes the disease overview and Wegener's Granulomatosis/Granulomatosis with Polyangiitis treatment guidelines. The assessment part of the report embraces, in depth Wegener's Granulomatosis/Granulomatosis with Polyangiitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wegener's Granulomatosis/Granulomatosis with Polyangiitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Wegener's Granulomatosis/Granulomatosis with Polyangiitis R&D. The therapies under development are focused on novel approaches to treat/improve Wegener's Granulomatosis/Granulomatosis with Polyangiitis.
Wegener's Granulomatosis/Granulomatosis with Polyangiitis Emerging Drugs Chapters
This segment of the Wegener's Granulomatosis/Granulomatosis with Polyangiitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Wegener's Granulomatosis/Granulomatosis with Polyangiitis Emerging Drugs
Abatacept: Bristol-Myers Squibb
Abatacept, sold under the brand name Orencia, inhibits T cell activation by selectively blocking specific binding of the CD80/CD86 receptor in APC to CD28 on T cells. The pharmacological strategy looks to inhibit the accelerated immune/inflammatory response, characteristic of the disease, and restore normal homeostasis in the immune system. The drug is currently in Phase III clinical studies for the treatment of relapsing, non-severe, granulomatosis with polyangiitis.
Vilobilemab: InflaRx
Vilobelimab (IFX 1; CaCP 29), is an anti-complement C5a monoclonal antibody. The drug is in Phase II clinical studies for the treatment of patients with granulomatosis with polyangiitis. Vilobelimab (IFX-1) holds large potential for treating various inflammatory disease and certain cancers and is in clinical testing for several indications, including hidradenitis suppurativa, ANCA-associated vasculitis and pyoderma gangraenosum.
Wegener's Granulomatosis/Granulomatosis with Polyangiitis: Therapeutic Assessment
This segment of the report provides insights about the different Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Wegener's Granulomatosis/Granulomatosis with Polyangiitis
There are approx. 2+ key companies which are developing the therapies for Wegener's Granulomatosis/Granulomatosis with Polyangiitis. The companies which have their Wegener's Granulomatosis/Granulomatosis with Polyangiitis drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.
Phases
This report covers around 2+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Wegener's Granulomatosis/Granulomatosis with Polyangiitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Wegener's Granulomatosis/Granulomatosis with Polyangiitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Wegener's Granulomatosis/Granulomatosis with Polyangiitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs.
Wegener's Granulomatosis/Granulomatosis with Polyangiitis Report Insights
- Wegener's Granulomatosis/Granulomatosis with Polyangiitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Wegener's Granulomatosis/Granulomatosis with Polyangiitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs?
- How many Wegener's Granulomatosis/Granulomatosis with Polyangiitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wegener's Granulomatosis/Granulomatosis with Polyangiitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Wegener's Granulomatosis/Granulomatosis with Polyangiitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Wegener's Granulomatosis/Granulomatosis with Polyangiitis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- InflaRx
- Bristol-Myers Squibb
Key Products
- Abatacept
- Vilobilemab
Table of Contents
IntroductionExecutive Summary
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Abatacept: Bristol-Myers Squibb
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Vilobilemab: InflaRx
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis Key Companies
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis Key Products
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis- Unmet Needs
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis- Market Drivers and Barriers
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis- Future Perspectives and Conclusion
Wegener’s Granulomatosis/Granulomatosis with Polyangiitis Analyst Views
AppendixList of Tables
Table 1 Total Products for Wegener's Granulomatosis/Granulomatosis with Polyangiitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Wegener’s Granulomatosis/Granulomatosis with Polyangiitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- InflaRx
- Bristol-Myers Squibb
